课题基金 / 基金详情

Ophthalmic Imaging Using Adaptive Optics and OCT

Ophthalmic Imaging Using Adaptive Optics and OCT
使用自适应光学和 OCT 进行眼科成像
批准号:
8326723
负责人:
JOHN S WERNER
金额:
$104.19万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-09-30 至 2014-08-31

项目摘要

项目成果

JOHN S WERNER的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):本BRP的目的是开发和评估活眼细胞的三维成像技术,并使用这项新技术来了解与导致全球范围内失明的最常见疾病相关的细胞层变化,包括老年性黄斑变性和青光眼。四个机构的合作伙伴将致力于将提供高横向分辨率的自适应光学(AO)与提供高轴向分辨率的光学相干层析成像(OCT)相结合的仪器。牵头机构是加州大学戴维斯分校(John S.Werner,PI)。加州大学戴维斯分校和印第安纳大学(Donald T.Miller,Site PI)都将开发和测试AO-OCT仪器。杜克大学(Joseph Izatt,Site PI)将开发新的OCT方法,并将纳入其中,而劳伦斯·利弗莫尔国家实验室(Score Olivier,Site PI)将提供AO方面的尖端技术。这些AO-OCT仪器将允许人体以足够的分辨率和对比度进行体内成像,以可视化人类视网膜中最小的细胞。在之前的项目期间,我们已经使用AO-OCT创建了以前只能用组织学才能看到的结构的体积图像,包括光感受器外段、Henle纤维、个别视神经纤维束、黄斑变性患者玻璃膜内的详细结构,以及视神经筛板的精细结构。在这次更新中,我们建议解决新的技术问题,以更充分地挖掘AO-OCT的潜力和功能。工程学的目标是通过使用自体荧光、双折射、结合“极端AO”技术来增强细胞结构的对比度,以及与血液灌流、视网膜血管中的血红蛋白氧饱和度以及神经细胞体积的电变化相关的功能变化。相当大的努力将致力于视网膜体积的三维可视化和分割,其侧向和轴向范围比以前可能的更大。这两个工程目标具有相同的临床目标,即提高我们对与老年性黄斑变性和青光眼标记物相关的细胞变化的理解。这些先进的成像技术将被用于评估视网膜和视神经的变化,这些变化是由拯救视网膜层的新疗法造成的,这些视网膜层是导致失明的主要原因。
英文摘要
DESCRIPTION (provided by applicant): The purpose of this BRP is to develop and evaluate technology for three-dimensional imaging of cells in the living eye, and to use this novel technology to understand changes in cell layers associated with the most common diseases leading to world-wide blindness, including age-related macular degeneration and glaucoma. Partners at four institutions will contribute to instrumentation that combines adaptive optics (AO), providing high lateral resolution, with optical coherence tomography (OCT), providing high axial resolution. The lead institution is the University of California, Davis (John S. Werner, PI). Both at UC Davis and at Indiana University (Donald T. Miller, site PI), AO-OCT instrumentation will be developed and tested. Duke University (Joseph Izatt, site PI) will develop novel OCT approaches that will be incorporated, while Lawrence Livermore National Laboratory (Scot Olivier, site PI) will provide cutting-edge advances in AO. These AO-OCT instruments will permit human in vivo imaging with sufficient resolution and contrast to visualize the smallest of cells in the human retina. In the previous project period we have used AO-OCT to create volume images of structures previously only visible with histology, including the photoreceptor outer segments, Fibers of Henle, individual optic nerve fiber bundles, detailed structures within drusen of macular degeneration patients, and fine structure of the lamina cribosa of the optic nerve. In this renewal, we propose to solve new technical issues to more fully tap the potential and functionality of AO-OCT. The engineering goals are directed toward increasing contrast of cellular structures by use of autofluoresence, birefringence, the incorporation of "extreme AO" techniques, and functional changes associated with blood perfusion, hemoglobin oxygen saturation in the retinal vasculature as well as electrical changes in neuronal cell volumes. Considerable effort will be devoted to three-dimensional visualization and segmentation over retinal volumes of larger lateral and axial extent than previously possible. The engineering goals have parallel clinical aims for improving our understanding of the cellular changes associated with markers for age-related macular degeneration and glaucoma. These advanced imaging techniques will be deployed for evaluating the changes in the retina and optic nerve resulting from novel therapies for rescuing retinal layers from the leading causes of blindness.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Structure and Function of the Chorioretinal Complex in Age-Related Macular Degene
Structure and Function of the Chorioretinal Complex in Age-Related Macular Degene
Structure and Function of the Chorioretinal Complex in Age-Related Macular Degene
NIAR01AG004058 Research Supplements to Promote Diversity in Health-Related Research
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: